What is OCGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.32B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OCGN?

P/E (TTM) is n/a and 52-week range is $0.90 to $2.73 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OCGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OCGN?

The company profile lists revenue (TTM) near $5M, net income (TTM) near $-6.41B, EPS (TTM) near $-0.20 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Ocugen Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Malvern, Pennsylvania, US, 338.5M shares outstanding, ISIN US67577C1053 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Ocugen Inc

$OCGN

Health Care · Biotechnology

IR Run Scenarios

$0.96

-2.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 116 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

Employees

116

Website

ocugen.com/

IPO

2014-12-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)